NDAORALCAPSULE, EXTENDED RELEASE
Approved
Aug 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
CREXONT (carbidopa and levodopa) by Viatris is dopa decarboxylase inhibitors [moa]. First approved in 2024.
Drug data last refreshed 4h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CREXONT is an extended-release oral capsule combining carbidopa and levodopa, approved August 2024 by Viatris for Parkinson's disease management. Levodopa is converted to dopamine in the brain to restore motor function, while carbidopa inhibits premature breakdown in the periphery. This formulation targets patients requiring optimized dopaminergic replacement with extended dosing convenience.
Growth15.2 years to LOE
Early-stage growth product with 15+ years of patent protection; commercial infrastructure still scaling with potential for field expansion.
Mechanism of Action
DOPA Decarboxylase Inhibitors
Pharmacologic Class:
Aromatic Amino Acid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide
Started Mar 2009
52 enrolled
Parkinson Disease
Career Relevance
CREXONT offers career opportunities in a mature therapeutic area with stable patient demand but increasing payer scrutiny. Viatris' franchise position in Parkinson's care means this role emphasizes managed care strategy, physician relationship-building, and competitive positioning against established alternatives.
Brand Manager
Worked on CREXONT at Viatris? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.